Stockscreener 앱 받기
0.7634
0.53%
-0.0041
시간 외 거래:
.75
-0.0134
-1.76%
전일 마감가:
$0.7675
열려 있는:
$0.7642
하루 거래량:
818.23K
Relative Volume:
0.30
시가총액:
$123.53M
수익:
$400.57M
순이익/손실:
$9.21M
주가수익비율:
19.08
EPS:
0.04
순현금흐름:
$146.36M
1주 성능:
+3.43%
1개월 성능:
+8.81%
6개월 성능:
-79.86%
1년 성능:
-88.64%
1일 변동 폭
$0.7501
$0.7993
1주일 범위
$0.6701
$0.82
52주 변동 폭
$0.5271
$7.105
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
IRWD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
0.7634 | 119.44M | 400.57M | 9.21M | 146.36M | 0.04 |
|
ZTS
Zoetis Inc
|
147.37 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.44 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.53 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.12 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
What analysts say about Ironwood Pharmaceuticals Inc. stockExceptional stock performance - PrintWeekIndia
What drives Ironwood Pharmaceuticals Inc. stock priceExceptional return forecasts - Autocar Professional
Is Ironwood Pharmaceuticals Inc. a good long term investmentBreakout profit opportunities - jammulinksnews.com
Ironwood Pharmaceuticals Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
How the Irritable Bowel Syndrome (IBS) Treatment Market Will - openPR.com
How Ironwood Pharmaceuticals Inc. stock performs during market volatilityTop Gaining Low Risk Assets - Newser
What makes Ironwood Pharmaceuticals Inc. stock price move sharplyFast Moving Stock Alerts - Newser
Why Ironwood Pharmaceuticals Inc. stock attracts strong analyst attentionHigh Confidence Trade Setups - Newser
Endometriosis Pain Pipeline 2025: FDA Updates, Therapy Innovations, And Clinical Trial Landscape Analysis By Delveinsight Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, Abbvie/Neurocrine - Menafn.com
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY By Investing.com - Investing.com Nigeria
Ironwood Pharmaceuticals appoints KPMG as new auditor, dismisses EY - Investing.com
Investor Network: Ironwood Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ironwood Pharmaceuticals, Inc.(NasdaqGS: IRWD) added to Russell 3000E Index - MarketScreener
Is Ironwood Pharmaceuticals, Inc. overvalued or undervalued? - MarketsMojo
Ironwood Pharma Elects Directors at Annual Meeting - TipRanks
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report? - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Is A Good Stock To Invest In - Stocksregister
Ameriprise Financial Inc. Trims Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer - GlobeNewswire
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock By Investing.com - Investing.com India
Ironwood Pharmaceuticals’ chief commercial officer sells $1,486 in stock - Investing.com Australia
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates - MSN
Drug developer stocks fall as companies navigate clinical roadblocks - BioWorld MedTech
Ironwood Pharma Stock Draws Retail Investor Ire With Big Q1 Miss And No Earnings Call - MSN
Brokerages Set Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Target Price at $4.78 - Defense World
Pacer Advisors, Inc. Reduces Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Pacer Advisors, Inc. Expands Stake in Ironwood Pharmaceuticals Inc. - GuruFocus
Ironwood: Q1 Earnings Snapshot - New Haven Register
Ironwood at The Citizens JMP Life Sciences Conference: Strategic Outlook By Investing.com - Investing.com India
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.68%
자본화:
|
볼륨(24시간):